Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Type 1 Diabetes

Type 1 Diabetes

Part of Diabetes

Subtypes of Type 1 Diabetes

Type 1 diabetes mellitus 14 Wolfram Syndrome 1

67 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Type 1 Diabetes

203 trials tracked for Type 1 Diabetes: 39 in phase 3 or 4 and 14 with published results. The most-cited published study has 181 citations.

203Trials tracked
39Phase 3 & 4
0Recruiting
14With published results
Phase distribution
Phase 4 14 Phase 3 25 Phase 2 29 Phase 1 9 Other / NA 126
  1. Phase 3 Metformin Therapy for Overweight Adolescents With Type 1 Diabetes Completed · 181 cited
  2. Phase 3 EMERALD: Effects of Metformin on Cardiovascular Function in Adolescents With Type 1 Diabetes Completed · 143 cited
  3. Phase 3 Efficacy Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Patients Completed · 58 cited
  4. Phase 3 A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy Completed · 50 cited
  5. Phase 4 52 Week Trial of Liraglutide in Type 1 Diabetes Completed · 38 cited
  6. Phase 4 Intravenous Insulin vs Subcutaneous Insulin Infusion in Intrapartum Management of Type 1 Diabetes Mellitus Completed · 15 cited
Show 44 more trials
  1. Phase 3 Targeting Inflammation With Salsalate in Type 1 Diabetes Neuropathy Completed · 12 cited
  2. Phase 4 Immune Intervention With Rituximab to Preserve Beta Cell Function in Early Onset Type 1 Diabetes Completed · 7 cited
  3. Phase 4 Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes Completed · 6 cited
  4. Phase 4 Human Versus Analogue Insulin for Youth With Type 1 Diabetes in Low-Resource Settings Completed · 5 cited
  5. Phase 3 Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1) Completed · 4 cited
  6. Phase 3 A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus Completed · 2 cited
  7. Phase 4 A Study to Evaluate Pneumococcal Polysaccharide Vaccine Effectiveness in Children With Type 1 Diabetes Completed · 1 cited
  8. Phase 4 A Study of Rapid-Acting Mealtime Insulin in Children and Adolescents With Newly Diagnosed Type 1 Diabetes Mellitus Completed · 1 cited
  9. Phase 4 Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia Completed
  10. Phase 4 Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes Completed
  11. Phase 4 New Onset Type 1 Diabetes: Role of Exenatide Completed
  12. Phase 4 Insulin Pump to Multiple Daily Injection Transition Clinical Trial Completed
  13. Phase 4 Effect of Metformin on Vascular and Mitochondrial Function in Type 1 Diabetes Completed
  14. Phase 4 Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose Completed
  15. Phase 4 Feasibility Study for Training Pump Naïve Subjects To Use The Paradigm® System And Evaluate Effectiveness Completed
  16. Phase 3 Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon Completed
  17. Phase 3 A Study of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Participants With Type 1 Diabetes Completed
  18. Phase 3 Liraglutide In Overweight Patients With Type 1 Diabetes Completed
  19. Phase 3 Effects of Acipimox on Insulin Action, Vascular Function, and Muscle Function in Type 1 Diabetes Completed
  20. Phase 3 Liraglutide in Type 1 Diabetes Completed
  21. Phase 3 Vitamin D and Residual Beta-Cell Function in Type 1 Diabetes Completed
  22. Phase 3 Liraglutide in Adolescents With Type 1 Diabetes Completed
  23. Phase 3 A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D Completed
  24. Phase 3 Study Comparing Effectiveness of Intraperitoneal Insulin Administration to Subcutaneous Insulin Administration Completed
  25. Phase 3 Comparison of Lantus and Neutral Protamine Hagedorn (NPH) Insulin in the Dawn Phenomenon Completed
  26. Phase 3 Outpatient Study to Evaluate Safety and Effectiveness of the Low Glucose Suspend Feature Completed
  27. Phase 3 STEP: Social Support To Empower Parents Completed
  28. Phase 3 Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes Completed
  29. Phase 3 Diabetic Retinopathy Candesartan Trials Completed
  30. Phase 3 New Strategies for Postprandial Glycemic Control Using Insulin Pump Therapy Completed
  31. Phase 3 DIabetic Retinopathy Candesartan Trials. Completed
  32. Phase 3 Liraglutide in the Treatment of Type 1 Diabetes Mellitus Completed
  33. Phase 3 Randomized Study of Real-Time Continuous Glucose Monitors (RT-CGM) in the Management of Type 1 Diabetes Completed
  34. Phase 2 Combination Therapy With Sitagliptin and Lansoprazole to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes Completed
  35. Phase 2 CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1 Completed
  36. Phase 2 Transdermal Basal Insulin Patch Study in Type 1 Diabetes Completed
  37. Phase 2 Incretin Effect and Use After Clinical Islet Transplantation Completed
  38. Phase 2 Naltrexone and Hypoglycemia in Type 1 Diabetes Completed
  39. Phase 2 Liraglutide Versus Insulin Mono-therapy in the Closed Loop Setting Completed
  40. Phase 2 Immune Effects of Oral Insulin in Relatives at Risk for Type 1 Diabetes Mellitus (TN20) Completed
  41. Phase 2 DiaBetter Together for Young Adults With Type 1 Diabetes Completed
  42. Phase 2 Diabetes Prevention - Immune Tolerance Completed
  43. Phase 2 Tauroursodeoxycholic Acid (TUDCA) in New-Onset Type 1 Diabetes Completed
  44. Phase 2 A Euglycemic Insulin Clamp Study in Type 1 Diabetic Patients With Oral Insulin (ORAMED) Completed

Showing the 50 most-cited and recently-updated of 203 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Type 1 Diabetes: what the trials found

Clinical trials for Type 1 Diabetes have evaluated various pharmacological and delivery interventions. Insulin Glargine was assessed regarding Time-in-Range (TIR), time in hypoglycemia, and time in serious hypoglycemia; however, no statistically significant differences were observed between groups across these metrics 14.

Multiple daily injections using a combination of Insulin Degludec and Insulin Aspart showed varying results compared to the control group: the treatment group had higher time spent with glucose levels >180 mg/dL (46.3% vs 38.5%), lower time in hypoglycemia <70 mg/dl (3.9% vs 2.1%), and lower Time-in-Range (47.8% vs 56.5%) 19.

Rapid-acting insulin was evaluated for its impact on caregiver treatment adherence and glycemic variability, with results showing significant differences in these metrics at the 1-month and 4-month post-intervention marks 16.

Insulin Degludec did not show statistically significant changes in mean percent Time in Range, Coefficient of Variation of TIR, or Nocturnal Time in Range (70-180 mg/dL) 17.

Recent results — preliminary, needs further review

  • The AIDANET system showed significantly higher TIR during 18-hour hotel sessions compared to at-home settings (85.7% vs 71.7%, p=0.02) 1.
  • Tandem t:slim X2 with extended bolus demonstrated a TIR of approximately 71-73% and 0% time in hypoglycemia 2.
  • MPC closed-loop systems showed significantly lower incremental Area Under the Curve of postprandial glucose following the first meal (18.1 vs 20.9, p=0.017) 6.
  • Psychoeducation to reduce diabetes distress did not result in statistically significant improvements in TIR, A1c, or distress scores 3.

For the clinician treating this condition

  • Insulin Glargine and Insulin Degludec showed no statistically significant differences in primary glycemic metrics such as Time-in-Range or hypoglycemia duration compared to controls [14, 17].
  • Combination therapy of Insulin Degludec and Insulin Aspart resulted in higher instances of hyperglycemia (>180 mg/dL) but lower rates of hypoglycemia (<70 mg/dl) compared to the control group 19.
  • Advanced delivery systems like AIDANET showed significantly improved Time-in-Range during specific high-variability scenarios (e.g., hotel sessions) compared to at-home settings 1.

AI synthesis of 8 cited trials, updated Jun 20, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Narrative review discusses CAR-T and HSC therapies for cancer and autoimmune conditions
Oncology Sys. Review
Narrative review discusses CAR-T and HSC therapies for cancer and autoimmune conditions Cancer Cell Therapy Gets Second Life Against Diabetes and MS
This narrative review examines the scope of chimeric antigen receptor T-cell (CAR-T), CAR-engineered regulatory T cell (CAR-Treg), and hemat…
• CAR-T cells trained to calm overactive immune systems show real promise • People with Type 1 diabetes or multiple sclerosis could benefit …
Frontiers May 4, 2026
Semaglutide reduces insulin dose in adults with type 1 diabetes and obesity
Nutrition & Obesity Medicine RCT
Semaglutide reduces insulin dose in adults with type 1 diabetes and obesity Semaglutide Cuts Insulin Needs By Half In Type 1 Diabetes
A post hoc analysis of an RCT found that semaglutide 1 mg/week significantly reduced total daily insulin dose by 22.6% over 26 weeks in adul…
Semaglutide reduces insulin needs quickly in type 1 diabetes patients, offering a new hope for better blood sugar control and weight managem…
Diab Care May 1, 2026
Umbrella review identifies risk factors and protective factors for male infertility and semen quality
Nutrition & Obesity Medicine Meta-analysis
Umbrella review identifies risk factors and protective factors for male infertility and semen quality New study lists many things that hurt male fertility and health
This umbrella review of 43 studies synthesizes evidence on risk factors for male infertility and abnormal semen parameters.
A new review shows that obesity, smoking, and certain illnesses can hurt sperm, but healthy habits might fix the problem.
May 1, 2026
Narrative review of transposable element methylation in autoimmune diseases
Diabetes & Endocrinology Sys. Review
Narrative review of transposable element methylation in autoimmune diseases Genetic elements may link autoimmune diseases to inflammation
This narrative review examines the role of transposable element (TE) methylation and expression in Type 1 diabetes, systemic lupus erythemat…
Changes in certain genetic elements could explain how the body triggers inflammation in diseases like lupus and rheumatoid arthritis.
Frontiers May 1, 2026
Meta-analysis finds slight IQ difference in children with type 1 diabetes versus peers
Diabetes & Endocrinology Meta-analysis
Meta-analysis finds slight IQ difference in children with type 1 diabetes versus peers Children with diabetes show slightly lower IQ scores than peers
This meta-analysis of 16 studies examined cognitive outcomes in children and adolescents with type 1 diabetes.
New research shows kids with type 1 diabetes may have slightly lower IQ scores but large groups show no reading or language gaps
Apr 29, 2026
Barriers and promoters to CGM and AID use in youth with T1D and public insurance
Diabetes & Endocrinology Cohort
Barriers and promoters to CGM and AID use in youth with T1D and public insurance New plan helps families with public insurance get life-saving diabetes tech
This prospective, mixed-methods study examined barriers and promoters to continuous glucose monitoring (CGM) and artificial insulin delivery…
A new study reveals why families with public insurance struggle to get diabetes tech and offers a custom plan to fix it.
Frontiers Apr 27, 2026
Beta-cell stress responses contribute to early Type 1 diabetes development and disease progression
Allergy & Immunology Cohort
Beta-cell stress responses contribute to early Type 1 diabetes development and disease progression Type 1 Diabetes May Start Inside the Cell, Not Just the Immune System
This perspective and review of human tissue, single cell transcriptomics, and longitudinal cohort studies indicates that beta-cell stress re…
This study shifts the focus of Type 1 diabetes from a pure immune problem to a two-part story where stressed cells play a key role.
Frontiers Apr 24, 2026
FDA Approves Tzield (teplizumab) to Delay Onset of Stage 3 Type 1 Diabetes
Diabetes & Endocrinology FDA Approval
FDA Approves Tzield (teplizumab) to Delay Onset of Stage 3 Type 1 Diabetes FDA approves Tzield to delay type 1 diabetes in high-risk patients
The FDA approved Tzield (teplizumab) to delay the onset of Stage 3 type 1 diabetes in patients aged 1 year and older with Stage 2 disease.
The FDA approved Tzield (teplizumab) to delay the onset of stage 3 type 1 diabetes in people aged 1 and older with stage 2 disease.
FDA Apr 24, 2026
Meta-analysis of sex differences in insulin therapy outcomes for adults with Type 1 and Type 2 diabetes
Diabetes & Endocrinology Meta-analysis
Meta-analysis of sex differences in insulin therapy outcomes for adults with Type 1 and Type 2 diabetes Women and Men Respond Differently to Insulin Therapy
This systematic review and meta-analysis evaluated sex differences in insulin therapy outcomes across 24 studies involving adults with Type …
Maria takes insulin every day for type 2 diabetes.
Apr 23, 2026
Meta-analysis of adjunctive SGLT2 inhibitors in type 1 diabetes shows mixed safety and efficacy signals
Diabetes & Endocrinology Meta-analysis
Meta-analysis of adjunctive SGLT2 inhibitors in type 1 diabetes shows mixed safety and efficacy signals No More Bone Fear With New Diabetes Drug
This meta-analysis evaluated adjunctive SGLT2 inhibitor therapy in 6,731 patients with type 1 diabetes mellitus receiving insulin-based ther…
Many people with type 1 diabetes worry about their bones.
Apr 22, 2026
Systematic review and meta-analysis of integrative therapies for Type 1 Diabetes Mellitus
Diabetes & Endocrinology Meta-analysis
Systematic review and meta-analysis of integrative therapies for Type 1 Diabetes Mellitus Yoga and Natural Therapies Help Control Type 1 Diabetes
This meta-analysis of 12 studies on integrative therapies for Type 1 Diabetes Mellitus found adjunctive benefits for glycemic control.
It’s 6 a.m. and 12-year-old Maya stirs awake.
Frontiers Apr 22, 2026
Autoimmune Thyroiditis Prevalence Higher in Obese Women With PCOS in Retrospective Cohort Analysis
OB/GYN & Women's Health Cohort
Autoimmune Thyroiditis Prevalence Higher in Obese Women With PCOS in Retrospective Cohort Analysis New PCOS Data Reveals Hidden Thyroid Risks
This retrospective cohort study evaluated 1,249 women with PCOS aged 18–44 years.
Women with PCOS should check their thyroid health regularly.
Frontiers Apr 22, 2026

Research across Diabetes

Related studies from across the Diabetes family.

Digital phenotyping enables real-time mental health monitoring and risk prediction in people with diabetes
Psychiatry Sys. Review
Digital phenotyping enables real-time mental health monitoring and risk prediction in people with diabetes Digital Tools May Help Track Mental Health in People with Diabetes
This scoping review of 10 studies examines the use of digital phenotyping, including CGM and smartphone sensing, for mental health monitorin…
New digital tools like smartphone sensors and glucose monitors may help track and predict mental health issues in people living with diabete…
Frontiers Oct 29, 2026
Prediction models for heart failure in type 2 diabetes show acceptable discrimination but lack prospective testing
Cardiology Meta-analysis
Prediction models for heart failure in type 2 diabetes show acceptable discrimination but lack prospective testing New Prediction Models Help Identify Heart Failure Risk in Diabetes
This meta-analysis of 65 studies evaluated prediction models for incident heart failure and heart failure hospitalization in people with typ…
New prediction models show promise in identifying heart failure risks for people living with type 2 diabetes.
Oct 29, 2026
Genome-wide meta-analysis identifies 25 trait-loci associations for cardiometabolic phenotypes in Native Hawaiian and Samoan populations
Diabetes & Endocrinology Meta-analysis
Genome-wide meta-analysis identifies 25 trait-loci associations for cardiometabolic phenotypes in Native Hawaiian and Samoan populations Native Hawaiian and Samoan DNA study finds new genetic links to diabetes risk
This meta-analysis of a genome-wide association study identifies 25 trait-loci associations for 13 adiposity and cardiometabolic traits in a…
A DNA study of 8,461 Native Hawaiians and Samoans found 25 genetic links to traits like blood sugar and body fat, including 5 that may be ne…
Oct 27, 2026
Adipo-B correlates with beta-cell indices in treatment-naive patients with Type 2 Diabetes
Diabetes & Endocrinology RCT
Adipo-B correlates with beta-cell indices in treatment-naive patients with Type 2 Diabetes New marker may help track insulin production in Type 2 Diabetes
This prospective, non-randomized observational study of 253 treatment-naive patients with Type 2 Diabetes found that adipo-B levels correlat…
A new protein marker could offer a simple way for doctors to track how well the body produces insulin in people with Type 2 Diabetes.
medRxiv Oct 27, 2026
Telemedicine for gestational diabetes reduces fasting glucose and gestational weight gain in women
Diabetes & Endocrinology Meta-analysis
Telemedicine for gestational diabetes reduces fasting glucose and gestational weight gain in women Telemedicine Shows Potential for Managing Gestational Diabetes Care
This meta-analysis of 3055 women with gestational diabetes found that telemedicine interventions associated with lower fasting glucose (MD -…
Telemedicine may help manage blood sugar and weight gain in pregnant women with gestational diabetes, though the evidence is currently limit…
Oct 24, 2026
Unhealthy food environments and ultra-processed foods contribute to obesity and related cardiometabolic diseases
Nutrition & Obesity Medicine Sys. Review
Unhealthy food environments and ultra-processed foods contribute to obesity and related cardiometabolic diseases Food Environments Linked to Obesity and Type 2 Diabetes
This narrative review examines how food environment factors like accessibility and affordability influence the consumption of ultra-processe…
Unhealthy food environments and ultra-processed foods are linked to serious conditions like insulin resistance, heart disease, and chronic k…
Frontiers Oct 23, 2026
High prevalence of vitamin B12 deficiency in South Asian pregnant women suggests risk for adverse outcomes
Nutrition & Obesity Medicine Sys. Review
High prevalence of vitamin B12 deficiency in South Asian pregnant women suggests risk for adverse outcomes Vitamin B12 deficiency is common among pregnant women in South Asia
This narrative review examines the prevalence of vitamin B12 deficiency in pregnant women in South Asia and its association with maternal an…
Up to 70% of pregnant women in South Asia may have low vitamin B12, a finding that could impact both mother and baby health.
Frontiers Oct 23, 2026
Retatrutide Shifts Fatty Acid Oxidation and Insulin Resistance Metabolites in Obesity Trials
Diabetes & Endocrinology RCT
Retatrutide Shifts Fatty Acid Oxidation and Insulin Resistance Metabolites in Obesity Trials New drug retatrutide shows promise for weight loss and diabetes
In phase 2 trials, retatrutide altered two metabolite clusters tied to fatty acid oxidation and insulin resistance, with ketone and acylcarn…
A new medication called retatrutide may help manage weight and insulin resistance by changing specific markers in the blood for people with …
Oct 22, 2026
Efficacy of Chinese Polyherbal Preparations Combined with Biomedicine for Diabetic Osteoporosis
Drug Pipeline Meta-analysis
Efficacy of Chinese Polyherbal Preparations Combined with Biomedicine for Diabetic Osteoporosis Herbal additions may improve outcomes for patients with diabetic osteoporosis
A network meta-analysis suggests that integrating specific Chinese polyherbal preparations with standard care improves bone density and gluc…
Combining specific herbal preparations with standard medicine may improve bone density and blood sugar for people with diabetic osteoporosis…
Frontiers Oct 22, 2026
Faecal microbiota transplantation did not significantly reduce HOMA-IR in patients with metabolic disorders
Diabetes & Endocrinology Meta-analysis
Faecal microbiota transplantation did not significantly reduce HOMA-IR in patients with metabolic disorders Fecal Microbiota Transplantation Shows Limited Benefit for Insulin Resistance
This meta-analysis of 6 trials involving 120 participants found that faecal microbiota transplantation did not significantly reduce HOMA-IR …
A review of clinical trials suggests that fecal microbiota transplantation may not significantly improve insulin resistance in people with t…
Frontiers Oct 17, 2026
Diabetic Retinopathy Tied to Higher Dementia Incidence in Pooled Analysis
Diabetes & Endocrinology Meta-analysis
Diabetic Retinopathy Tied to Higher Dementia Incidence in Pooled Analysis Diabetes eye damage may link to higher risk of dementia
Pooled data from nearly 3 million patients link diabetic retinopathy to higher incident dementia, though crude analyses show no significant …
A large study of over 2 million people suggests that eye damage from diabetes is linked to a higher risk of developing dementia.
Frontiers Oct 15, 2026
Cryptococcal meningitis with sequential cerebral infarctions and autonomic dysfunction in a non-HIV man with type 2 diabetes
Urology Sys. Review
Cryptococcal meningitis with sequential cerebral infarctions and autonomic dysfunction in a non-HIV man with type 2 diabetes Antifungal treatment helps man with diabetes and brain infection
This case report and focused literature review describes a 66-year-old non-HIV man with type 2 diabetes who developed cryptococcal meningiti…
A man with type 2 diabetes and a brain infection showed significant improvement after receiving a specific combination of antifungal medicat…
Frontiers Oct 15, 2026

Questions about Type 1 Diabetes

Does the FDA approved drug Tzield delay the onset of Stage 3 Type 1 diabetes?

Yes, the FDA-approved drug Tzield (teplizumab) delays the onset of Stage 3 type 1 diabetes in people with Stage 2 disease.

Full answer →
Can semaglutide help reduce the total daily insulin dose for adults with Type 1 diabetes?

Yes, semaglutide can reduce total daily insulin dose in adults with type 1 diabetes and overweight or obesity, based on clinical trial and real-world data.

Full answer →